155 related articles for article (PubMed ID: 8252351)
1. Correlation between p53 mutations and antibody staining in breast carcinoma.
Dunn JM; Hastrich DJ; Newcomb P; Webb JC; Maitland NJ; Farndon JR
Br J Surg; 1993 Nov; 80(11):1410-2. PubMed ID: 8252351
[TBL] [Abstract][Full Text] [Related]
2. p53 mutations and overexpression in locally advanced breast cancers.
Faille A; De Cremoux P; Extra JM; Linares G; Espie M; Bourstyn E; De Rocquancourt A; Giacchetti S; Marty M; Calvo F
Br J Cancer; 1994 Jun; 69(6):1145-50. PubMed ID: 8198984
[TBL] [Abstract][Full Text] [Related]
3. Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma.
Visscher DW; Sarkar FH; Shimoyama RK; Crissman JD
Diagn Mol Pathol; 1996 Sep; 5(3):187-93. PubMed ID: 8866232
[TBL] [Abstract][Full Text] [Related]
4. P53 in breast carcinomas: association between presence of mutation and immunohistochemical expression using a semiquantitative approach.
Schmitt FC; Soares R; Cirnes L; Seruca R
Pathol Res Pract; 1998; 194(12):815-9. PubMed ID: 9894246
[TBL] [Abstract][Full Text] [Related]
5. Detecting p53 gene mutation of breast cancer and defining differences between silver staining PCR-SSCP and immunohistochemical staining.
Ryu JW; Lee MC; Jang WC
J Korean Med Sci; 2000 Feb; 15(1):73-7. PubMed ID: 10719813
[TBL] [Abstract][Full Text] [Related]
6. Identification of p53 mutations by means of single strand conformation polymorphism analysis in gynaecological tumours: comparison with the results of immunohistochemistry.
Schneider J; Rubio MP; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
Eur J Cancer; 1994; 30A(4):504-8. PubMed ID: 8018409
[TBL] [Abstract][Full Text] [Related]
7. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques.
Hurlimann J; Chaubert P; Benhattar J
Mod Pathol; 1994 May; 7(4):423-8. PubMed ID: 8066070
[TBL] [Abstract][Full Text] [Related]
8. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing.
Chakravarty G; Redkar A; Mittra I
Br J Cancer; 1996 Oct; 74(8):1181-7. PubMed ID: 8883402
[TBL] [Abstract][Full Text] [Related]
10. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer.
Lisboa BW; Vogtländer S; Gilster T; Riethdorf L; Milde-Langosch K; Löning T
Virchows Arch; 1997 Dec; 431(6):375-81. PubMed ID: 9428925
[TBL] [Abstract][Full Text] [Related]
11. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
12. The role of p53 mutations in bilateral breast carcinoma.
Ackerman J; Baunoch DA; Gimotty P; George J; Lane MA; Dawson PJ
Mod Pathol; 1995 Apr; 8(3):244-8. PubMed ID: 7617647
[TBL] [Abstract][Full Text] [Related]
13. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
14. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.
Gumerlock PH; Chi SG; Shi XB; Voeller HJ; Jacobson JW; Gelmann EP; deVere White RW
J Natl Cancer Inst; 1997 Jan; 89(1):66-71. PubMed ID: 8978408
[TBL] [Abstract][Full Text] [Related]
15. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
17. p53 oncogene mutations in human prostate cancer specimens.
Voeller HJ; Sugars LY; Pretlow T; Gelmann EP
J Urol; 1994 Feb; 151(2):492-5. PubMed ID: 7904314
[TBL] [Abstract][Full Text] [Related]
18. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
[TBL] [Abstract][Full Text] [Related]
19. Expression of biomarkers (p53, transforming growth factor alpha, epidermal growth factor receptor, c-erbB-2/neu and the proliferative cell nuclear antigen) in oropharyngeal squamous cell carcinomas.
Ibrahim SO; Lillehaug JR; Johannessen AC; Liavaag PG; Nilsen R; Vasstrand EN
Oral Oncol; 1999 May; 35(3):302-13. PubMed ID: 10621852
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.
Thorlacius S; Thorgilsson B; Björnsson J; Tryggvadottir L; Börresen AL; Ogmundsdottir HM; Eyfjörd JE
Eur J Cancer; 1995 Oct; 31A(11):1856-61. PubMed ID: 8541113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
